Structure Therapeutics (NASDAQ:GPCR) Trading Down 5.5%

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares fell 5.5% during trading on Tuesday . The company traded as low as $41.96 and last traded at $41.96. 292,108 shares changed hands during trading, a decline of 50% from the average session volume of 586,402 shares. The stock had previously closed at $44.41.

Analyst Ratings Changes

A number of research firms have commented on GPCR. Cantor Fitzgerald began coverage on shares of Structure Therapeutics in a report on Tuesday. They set an "overweight" rating and a $65.00 target price for the company. Lifesci Capital reaffirmed an "outperform" rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $85.71.

Structure Therapeutics Trading Down 6.6 %

The company has a market cap of $1.93 billion and a price-to-earnings ratio of -50.39. The firm's fifty day moving average price is $41.76 and its 200-day moving average price is $48.70.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. As a group, research analysts anticipate that Structure Therapeutics Inc. will post -0.96 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its holdings in shares of Structure Therapeutics by 404.0% in the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company's stock valued at $178,216,000 after purchasing an additional 3,504,747 shares during the period. Adage Capital Partners GP L.L.C. raised its holdings in shares of Structure Therapeutics by 835.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company's stock valued at $90,752,000 after purchasing an additional 1,607,525 shares during the period. Avoro Capital Advisors LLC raised its holdings in shares of Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company's stock valued at $95,107,000 after purchasing an additional 1,333,333 shares during the period. FMR LLC bought a new stake in shares of Structure Therapeutics in the 1st quarter valued at about $29,724,000. Finally, Federated Hermes Inc. raised its holdings in shares of Structure Therapeutics by 104.2% in the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company's stock valued at $92,411,000 after purchasing an additional 1,157,006 shares during the period. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.